A new drug, ANX007, could be the first to protect vision in people with dry age-related macular degeneration (AMD). In the Phase 2 ARCHER study, monthly injections of ANX007 cut the risk of significant vision loss by 72% and preserved key retinal structures essential for vision. The developer of the drug, Annexon, plans on sharing…
Astellas Pharma’s $1.7B Iveric Bio buy aims to bolster its ophthalmology market position
Astellas Pharma, the second largest Japanese pharma firm after Takeda, plans on scooping up the biopharma Iveric Bio for roughly $1.7 billion. Iveric focuses on discovering and developing novel therapies for retinal diseases, for approximately $1.7 billion. Astellas believes the acquisition of Iveric Bio will strengthen its standing in the ophthalmology market, by adding the…